Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195


Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer.

Goggin KP, Gonzalez-Pena V, Inaba Y, Allison KJ, Hong DK, Ahmed AA, Hollemon D, Natarajan S, Mahmud O, Kuenzinger W, Youssef S, Brenner A, Maron G, Choi J, Rubnitz JE, Sun Y, Tang L, Wolf J, Gawad C.

JAMA Oncol. 2019 Dec 19. doi: 10.1001/jamaoncol.2019.4120. [Epub ahead of print]


Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.

Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, Campana D, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Khan RB, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV, Pui CH.

J Clin Oncol. 2019 Dec 10;37(35):3377-3391. doi: 10.1200/JCO.19.01692. Epub 2019 Oct 28.


A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.

Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, Fan Y, Gruber TA, Baker S, Klco J, Rubnitz JE, Pounds S, Lamba JK.

Leukemia. 2019 Oct 23. doi: 10.1038/s41375-019-0604-8. [Epub ahead of print]


Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.

Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz JE, Baker SD.

Clin Cancer Res. 2019 Dec 15;25(24):7320-7330. doi: 10.1158/1078-0432.CCR-19-0470. Epub 2019 Aug 27.


Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.

Buelow DR, Pounds SB, Wang YD, Shi L, Li Y, Finkelstein D, Shurtleff S, Neale G, Inaba H, Ribeiro RC, Palumbo R, Garrison D, Orwick SJ, Blachly JS, Kroll K, Byrd JC, Gruber TA, Rubnitz JE, Baker SD.

Clin Transl Sci. 2019 Nov;12(6):641-647. doi: 10.1111/cts.12669. Epub 2019 Aug 20.


Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.

Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner RA, Kotecha RS, Lausen B, Li CK, Locatelli F, Attarbaschi A, Peters C, Rubnitz JE, Silverman LB, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi MG.

J Clin Oncol. 2019 Sep 1;37(25):2246-2256. doi: 10.1200/JCO.19.00261. Epub 2019 Jul 8.


Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.

Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui CH.

J Clin Oncol. 2019 Aug 10;37(23):2072-2081. doi: 10.1200/JCO.19.00327. Epub 2019 Jun 27.


A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.

Drenberg CD, Shelat A, Dang J, Cotton A, Orwick SJ, Li M, Jeon JY, Fu Q, Buelow DR, Pioso M, Hu S, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, Guy RK, Baker SD.

Nat Commun. 2019 May 16;10(1):2189. doi: 10.1038/s41467-019-09917-0.


Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.

Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, Litzow M, Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N, Kirby S, Liu A, Massaro S, Mattison RJ, Oluwole O, Papadantonakis N, Park J, Rubnitz JE, Uy GL, Gregory KM, Ogba N, Shah B.

J Natl Compr Canc Netw. 2019 May 1;17(5):414-423. doi: 10.6004/jnccn.2019.0024.


A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.

Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro RC, Cullins D, Rooney B, Bell T, Lacayo NJ, Heym K, Degar B, Schiff D, Janssen WE, Triplett B, Pui CH, Leung W, Rubnitz JE.

J Immunother Cancer. 2019 Mar 20;7(1):81. doi: 10.1186/s40425-019-0564-6.


Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML.

Bargal SA, Rafiee R, Crews KR, Wu H, Cao X, Rubnitz JE, Ribeiro RC, Downing JR, Pounds SB, Lamba JK.

Oncotarget. 2018 Oct 9;9(79):34859-34875. doi: 10.18632/oncotarget.26163. eCollection 2018 Oct 9.


The genetic basis and cell of origin of mixed phenotype acute leukaemia.

Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG.

Nature. 2018 Oct;562(7727):373-379. doi: 10.1038/s41586-018-0436-0. Epub 2018 Sep 12.


Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies.

Robinson KM, Yang W, Haidar CE, Hankins JS, Jay DW, Kornegay N, Rubnitz JE, Broeckel U, Cheng C, Pui CH, Jeha S, Relling MV.

Pharmacogenomics J. 2019 Jun;19(3):305-314. doi: 10.1038/s41397-018-0043-3. Epub 2018 Sep 12.


Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.

Lamba JK, Cao X, Raimondi SC, Rafiee R, Downing JR, Shi L, Gruber T, Ribeiro RC, Rubnitz JE, Pounds SB.

Oncotarget. 2018 Jul 13;9(54):30473. doi: 10.18632/oncotarget.25792. eCollection 2018 Jul 13.


Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.

Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK.

Pharmacogenomics. 2018 Sep 1;19(14):1101-1110. doi: 10.2217/pgs-2018-0086. Epub 2018 Aug 8.


Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.

Lamba JK, Cao X, Raimondi SC, Rafiee R, Downing JR, Lei S, Gruber T, Ribeiro RC, Rubnitz JE, Pounds SB.

Oncotarget. 2018 Jun 1;9(42):26711-26723. doi: 10.18632/oncotarget.25475. eCollection 2018 Jun 1. Erratum in: Oncotarget. 2018 Jul 13;9(54):30473.


Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial.

Wolf J, Connell TG, Allison KJ, Tang L, Richardson J, Branum K, Borello E, Rubnitz JE, Gaur AH, Hakim H, Su Y, Federico SM, Mechinaud F, Hayden RT, Monagle P, Worth LJ, Curtis N, Flynn PM.

Lancet Infect Dis. 2018 Aug;18(8):854-863. doi: 10.1016/S1473-3099(18)30224-X. Epub 2018 Jun 5.


POST: A framework for set-based association analysis in high-dimensional data.

Cao X, George EO, Wang M, Armstrong DB, Cheng C, Raimondi S, Rubnitz JE, Downing JR, Kundu M, Pounds SB.

Methods. 2018 Aug 1;145:76-81. doi: 10.1016/j.ymeth.2018.05.011. Epub 2018 May 17.


Universal monitoring of minimal residual disease in acute myeloid leukemia.

Coustan-Smith E, Song G, Shurtleff S, Yeoh AE, Chng WJ, Chen SP, Rubnitz JE, Pui CH, Downing JR, Campana D.

JCI Insight. 2018 May 3;3(9). pii: 98561. doi: 10.1172/jci.insight.98561.


Bone mineral density in children with acute lymphoblastic leukemia.

Inaba H, Cao X, Han AQ, Panetta JC, Ness KK, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Cheng C, Pui CH, Relling MV, Kaste SC.

Cancer. 2018 Mar 1;124(5):1025-1035. doi: 10.1002/cncr.31184. Epub 2017 Dec 19.


Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.

Sun Y, Huskey RL, Tang L, Inaba H, Gaur AH, Ribeiro R, Rubnitz JE, Wolf J.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01838-17. doi: 10.1128/AAC.01838-17. Print 2018 Mar.


Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.

van Oosterwijk JG, Buelow DR, Drenberg CD, Vasilyeva A, Li L, Shi L, Wang YD, Finkelstein D, Shurtleff SA, Janke LJ, Pounds S, Rubnitz JE, Inaba H, Pabla N, Baker SD.

J Clin Invest. 2018 Jan 2;128(1):369-380. doi: 10.1172/JCI91893. Epub 2017 Dec 11.


Genetics of pleiotropic effects of dexamethasone.

Ramsey LB, Pounds S, Cheng C, Cao X, Yang W, Smith C, Karol SE, Liu C, Panetta JC, Inaba H, Rubnitz JE, Metzger ML, Ribeiro RC, Sandlund JT, Jeha S, Pui CH, Evans WE, Relling MV.

Pharmacogenet Genomics. 2017 Aug;27(8):294-302. doi: 10.1097/FPC.0000000000000293.


Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.

Alexander TB, Wang L, Inaba H, Triplett BM, Pounds S, Ribeiro RC, Pui CH, Rubnitz JE.

Cancer. 2017 Oct 1;123(19):3791-3798. doi: 10.1002/cncr.30791. Epub 2017 May 30.


Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada.

Alexander TB, Bhakta N, Kolb EA, Rubnitz JE.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26632. Epub 2017 May 16. No abstract available.


Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.

Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, Pappo AS, Jeha S, Pui CH, Relling MV.

Cancer. 2017 Sep 15;123(18):3602-3608. doi: 10.1002/cncr.30762. Epub 2017 May 11.


Infection-related complications during treatment for childhood acute lymphoblastic leukemia.

Inaba H, Pei D, Wolf J, Howard SC, Hayden RT, Go M, Varechtchouk O, Hahn T, Buaboonnam J, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Cheng C, Evans WE, Relling MV, Pui CH.

Ann Oncol. 2017 Feb 1;28(2):386-392. doi: 10.1093/annonc/mdw557.


The genomic landscape of core-binding factor acute myeloid leukemias.

Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z, Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LL, Easton J, Parganas E, Pui CH, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Döhner K, Döhner H, Bullinger L, Zhang J, Klco JM, Downing JR.

Nat Genet. 2016 Dec;48(12):1551-1556. doi: 10.1038/ng.3709. Epub 2016 Oct 31.


Current Management of Childhood Acute Myeloid Leukemia.

Rubnitz JE.

Paediatr Drugs. 2017 Feb;19(1):1-10. doi: 10.1007/s40272-016-0200-6. Review.


Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.

Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, Hageman L, Chen Y, Yang JJ, Crews KR, Kornegay N, Karol SE, Wong FL, Jeha S, Sandlund JT, Ribeiro RC, Rubnitz JE, Metzger ML, Pui CH, Evans WE, Bhatia S, Relling MV.

Clin Pharmacol Ther. 2017 Mar;101(3):373-381. doi: 10.1002/cpt.463. Epub 2016 Nov 18.


Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Gruber TA, Leung WH, Yang JJ, Downing JR, Evans WE, Relling MV, Campana D.

Leukemia. 2017 Feb;31(2):333-339. doi: 10.1038/leu.2016.234. Epub 2016 Aug 18.


Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.

Alexander TB, Lacayo NJ, Choi JK, Ribeiro RC, Pui CH, Rubnitz JE.

J Clin Oncol. 2016 Dec;34(34):4094-4101. Epub 2016 Oct 31.


Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation.

Drenberg CD, Buelow DR, Pounds SB, Wang YD, Finkelstein D, Rahija RJ, Shurtleff SA, Rubnitz JE, Inaba H, Gruber TA, Klco JM, Baker SD.

Leuk Lymphoma. 2017 Jan;58(1):247-250. Epub 2016 Jun 1. No abstract available.


Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.

Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD.

Clin Pharmacol Ther. 2016 Jun;99(6):651-60. doi: 10.1002/cpt.315. Epub 2016 Feb 20.


Clinical significance of in vivo cytarabine-induced gene expression signature in AML.

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE.

Leuk Lymphoma. 2016;57(4):909-20. doi: 10.3109/10428194.2015.1086918. Epub 2015 Oct 16.


Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study.

Wolf J, Tang L, Rubnitz JE, Brennan RC, Shook DR, Stokes DC, Monagle P, Curtis N, Worth LJ, Allison K, Sun Y, Flynn PM.

PLoS One. 2015 Aug 31;10(8):e0135904. doi: 10.1371/journal.pone.0135904. eCollection 2015.


Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B, Dworzak M, Gibson BE, Hasle H, Leverger G, Locatelli F, Ragu C, Ribeiro RC, Rizzari C, Rubnitz JE, Smith OP, Sung L, Tomizawa D, van den Heuvel-Eibrink MM, Creutzig U, Kaspers GJ.

J Clin Oncol. 2015 Sep 20;33(27):2949-62. doi: 10.1200/JCO.2015.62.8289. Epub 2015 Aug 24. Review.


New approaches for the immunotherapy of acute myeloid leukemia.

Geiger TL, Rubnitz JE.

Discov Med. 2015 Apr;19(105):275-84. Review.


Natural killer cell therapy in children with relapsed leukemia.

Rubnitz JE, Inaba H, Kang G, Gan K, Hartford C, Triplett BM, Dallas M, Shook D, Gruber T, Pui CH, Leung W.

Pediatr Blood Cancer. 2015 Aug;62(8):1468-72. doi: 10.1002/pbc.25555. Epub 2015 Apr 30.


Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.

Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Bhojwani D, Gruber TA, Leung WH, Downing JR, Evans WE, Relling MV, Campana D.

Lancet Oncol. 2015 Apr;16(4):465-74. doi: 10.1016/S1470-2045(15)70082-3. Epub 2015 Mar 20.


Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids.

Kaste SC, Pei D, Cheng C, Neel MD, Bowman WP, Ribeiro RC, Metzger ML, Bhojwani D, Inaba H, Campbell P, Rubnitz JE, Jeha S, Sandlund JT, Downing JR, Relling MV, Pui CH, Howard SC.

J Clin Oncol. 2015 Feb 20;33(6):610-5. doi: 10.1200/JCO.2014.57.5480. Epub 2015 Jan 20.


Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.

Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H.

Br J Haematol. 2015 Jan;168(1):94-101. doi: 10.1111/bjh.13107. Epub 2014 Aug 28.


Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?

O'Hear C, Rubnitz JE.

Expert Rev Hematol. 2014 Aug;7(4):427-9. doi: 10.1586/17474086.2014.924849. Epub 2014 May 29.


Definition of cure in childhood acute myeloid leukemia.

Rubnitz JE, Inaba H, Leung WH, Pounds S, Cao X, Campana D, Ribeiro RC, Pui CH.

Cancer. 2014 Aug 15;120(16):2490-6. doi: 10.1002/cncr.28742. Epub 2014 May 2.


A revised definition for cure of childhood acute lymphoblastic leukemia.

Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S, Howard SC, Bhojwani D, Inaba H, Rubnitz JE, Metzger ML, Gruber TA, Coustan-Smith E, Downing JR, Leung WH, Relling MV, Evans WE.

Leukemia. 2014 Dec;28(12):2336-43. doi: 10.1038/leu.2014.142. Epub 2014 Apr 30.


Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.

Inaba H, Gaur AH, Cao X, Flynn PM, Pounds SB, Avutu V, Marszal LN, Howard SC, Pui CH, Ribeiro RC, Hayden RT, Rubnitz JE.

Cancer. 2014 Jul 1;120(13):1985-92. doi: 10.1002/cncr.28688. Epub 2014 Mar 26.


Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.

Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, Krull KR, Inaba H, Rubnitz JE, Metzger ML, Howard SC, Ribeiro RC, Cheng C, Reddick WE, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV.

J Clin Oncol. 2014 Mar 20;32(9):949-59. doi: 10.1200/JCO.2013.53.0808. Epub 2014 Feb 18.


Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Jeha S, Coustan-Smith E, Pei D, Sandlund JT, Rubnitz JE, Howard SC, Inaba H, Bhojwani D, Metzger ML, Cheng C, Choi JK, Jacobsen J, Shurtleff SA, Raimondi S, Ribeiro RC, Pui CH, Campana D.

Cancer. 2014 May 15;120(10):1514-9. doi: 10.1002/cncr.28598. Epub 2014 Feb 5.


RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK.

Pharmacogenomics. 2013 Sep;14(12):1449-66. doi: 10.2217/pgs.13.131.


Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE.

Cancer. 2013 Nov 15;119(22):4036-43. doi: 10.1002/cncr.28334. Epub 2013 Sep 4.

Supplemental Content

Loading ...
Support Center